The Future is In-Vivo

Dr. Geerlings is an experienced executive and serial entrepreneur who has co-founded and led multiple successful biotech companies . In 2000, he co-founded Actinium Pharmaceuticals Inc., a company listed on the New York Stock Exchange (NYSE: ATNM). In 2010, he established Formula Pharmaceuticals Inc., which was subsequently sold in 2020. In 2017, he co-founded Mirata Pharmaceuticals and  launched NanoCell Therapeutics in 2021, both companies securing venture capital funding.

Dr. Geerlings played a key role as the Executive Vice President and Chief Operating Officer in Actinium Pharmaceuticals Inc., From 2002 to 2010, he has been actively involved in business development for Alexion Pharmaceuticals Inc., Cephalon, Inc., Prism Pharmaceuticals, and Infinity Pharmaceuticals.

Throughout his career, he has successfully navigated complex negotiations and spearheaded strategic partnerships. With extensive expertise in deal making, Dr. Geerlings has established alliances through out-licensing, in-licensing, M&A, plus co-development initiatives, spanning both domestic and international markets, including the USA and Europe.

Dr. Geerlings earned his MD from the University of Utrecht in The Netherlands and obtained his Executive MBA from the George Washington University, Washington, DC. 

Mr. Lubelski is an accomplished biopharmaceutical leader, researcher and pharmaceutical developerspecializing in gene and cell therapy and viral vector production. With over a decade-long career, he has made significant contributions to the development and advancement of gene therapy technologies, particularly in the field of recombinant adeno-associated virus (rAAV) therapeutics.

Prior to joining NanoCell Therapeutics, Mr. Lubelski served as the VP of Pharmaceutical Development at UniQure NV (NASDAQ: QURE), where he contributed to obtaining market authorization for Glybera, the first approved gene therapy medicine in the Western World, to treat lipoprotein lipase ( LPL) deficiency. He has been instrumental in developing multiple rAAV-based translational advanced therapy medicinal products (ATMPs) to address challenging diseases like Haemophilia B, Sanphilipo B, and Acute Intermittent Porfyria. As Vice President of Development, Mr. Lubelski also led vector development, process development, analytical methods, pre-clinical studies, and CMC activities focused on rAAV-based therapies. His expertise in leading complex teams across Europe and the USA has resulted in successful design and implementation of technological processes and analytical methods for viral vector manufacturing platforms.

In his current role as the Chief Technology Officer at NanoCell Therapeutics, Mr. Lubelski spearheads all research and development activities. Beyond his leadership roles, he has played pivotal roles in collaborative projects with renowned institutions and organizations such as Synpromics and 4D Molecular Therapeutics, contributing to the development of improved promoters and capsids for human gene therapy. Dr. Lubelski was also selected as an expert by the European Directorate for the Quality of Medicines & Healthcare (EDQM) to contribute to the revision of gene therapy guidance, highlighting his deep knowledge, expertise, and contributions to shaping the future of gene therapies. He has coauthored more then 20 scientific publications as well as multiple patent applications pertaining to gene therapy filed.

Mr. Lubelski holds a Ph.D. in Molecular Microbiology from the University of Groningen and a Master's degree in Biotechnology from Maria Curie-Sklodowska University in Lublin, Poland. He is currently pursuing eMBA studies at the Rotterdam School of Management, Erasmus University in Rotterdam, the Netherlands.

With over 10 years experience in the life sciences industry, Ms. Midha brings a robust background to her role at NanoCell, where she spearheads the company's financial management.

Ms. Midha is also the Chief Financial Officer at Mirata Pharmaceuticals, a company developing a gene therapy for intractable pain. Prior to her tenure at Mirata, she served for eight years as the CFO of iCeutica Inc., a company fueling new product development and solving problems of bioavailability, variability, side effects of pharmaceuticals using its SoluMatrix™ Fine Particle Technology. While at iCeutica, Ms Midha alsoserved asacting CFO at Churchill Pharmaceuticals LLC, a company developing a novel formulation of abiraterone using the SoluMatrix technology.. Both companies made significant strides in pharmaceutical research and development, boasting a combined total of four FDA-approved products. Before making her mark at these companies, Ms. Midha held various finance and accounting positions at C&D Technologies, L'Oreal, Honeywell, and Ingersoll-Rand.

Besides her excellence in financial leadership, Ms. Midha presently leverages her expertise in human resource management and corporate insurance for clients, through Midha Consulting, LLC.

Ms. Midha's holds an MBA from the University of Chicago and a BS in Accounting and International Business from King's College, London, UK.

Dr. Schiffelers holds a prominent role as a senior member of NanoCell's R&D team, while being Professor of Nanomedicine at the University Medical Center Utrecht (UMCU). Additionally, he serves as the head of research at the Central Diagnostic Laboratory (CDL) within the Division of Laboratories, Pharmacy & Biomedical Genetics at the UMCU.

Under Dr. Schiffelers' guidance, the CDL research team has developed strong expertise in synthetic drug delivery systems and RNA delivery, making notable contributions to the field. Moreover, the Division is actively engaged in the emerging and promising area of extracellular vesicles, further solidifying its position at the forefront of scientific advancements. As a distinguished Professor, Dr. Schiffelers takes responsibility for coordinating the Masters course in Nanomedicine. He also lectures on Pharmaceutical Biotechnology, Nanomedicine, Nanotechnology, and Hematology.

At the institutional level of the University Medical Center Utrecht (UMCU), Dr. Schiffelers plays a crucial role. Given his extensive track record and expertise, he primarily focuses on providing grant advice to support research initiatives. Additionally, he spearheads efforts to reform and enhance the evaluation of scientific practices at UMCU, driving progress and fostering a culture of excellence. Dr. Schiffelers' dedication to advancing scientific knowledge, coupled with his multidisciplinary expertise, positions him as a key member and advisor to NanoCell.

In 2021, Dr. Schiffelers was elected as the President of the European Technology Platform and continues in this capacity. This appointment further exemplifies his role in shaping the future of nanomedicine and driving innovation at the European level.

Stephen A. Jannetta is a highly engaged professional who actively contributes to both the legal and business communities. He specializes in delivering expert corporate advice and counsel to a diverse range of clients, including those in the for-profit and nonprofit sectors within industries such as life sciences, healthcare and healthcare insurance, health information technology, technology, energy, and financial services.

Mr. Jannetta's client portfolio encompasses both public and privately held corporations, as well as nonprofit organizations. He consistently provides guidance on intricate matters, including financing transactions, M&A, securities law issues, joint ventures, corporate governance, and technology licensing transactions. His strategic insights and legal guidance contribute significantly to Nanocells’ achievements, making him an indispensable advisor in the pursuit of Nanocell’s business goals.